Lung Cancer
Conditions
Interventions
Observation group:None
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: - Advanced ALK+ NSCLC diagnosed by pathohistology and/or cytology This study is a real-world study and can be considered for inclusion in patients with advanced non-small cell lung cancer who have received lorlatinib as the initial or subsequent line of therapy and have detailed medical information. Patients with advanced ALK+ NSCLC confirmed by histopathological and/or cytological examination ECOG score 0-2 points Age 18 to 80 years old Take lorlatinib for at least 20 days Eligible for the first phase of the study subject exempt from informed consent, with information confidentiality instructions In the second stage, the study subjects need to sign the informed consent form, have good compliance, and cooperate with the follow-up
Exclusion criteria
Exclusion criteria: Treatment with other anti-cancer drugs during lorlatinib treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3m-concentrations;Hypersensitive C-reactive protein;IL-6;cIMT;Coronary calcification score; | — |
Countries
China
Contacts
Public ContactLiang Li
Peking University Third Hospital
Outcome results
None listed